Xenotransplantation is the fusion energy of medicine. As the well-worn joke goes, it is the future—and always will be. But ...

Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock fell 19% after the market close Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Phase 3 ...

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of ...

Advancements in gene-editing technology are propelling xenotransplantation, potentially addressing organ shortage with pig organs modified for human compatibility.

USA-based Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase ...

Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

The company said dosing in its Phase III MAGNITUDE-1 and MAGNITUDE-2 studies for transthyretin amyloidosis (ATTR) had been voluntarily paused after a patient in the cardiomyopathy trial was ...

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

摘要： 美国生物科技公司 Intellia Therapeutics 因一名患者出现严重肝安全信号，紧急暂停两款 CRISPR 疗法 Ⅲ 期临床试验。受此影响，公司股价早盘暴跌 ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...